294 related articles for article (PubMed ID: 25375891)
41. Antiangiogenic therapy in leukemia.
Thomas DA; Giles FJ; Cortes J; Albitar M; Kantarjian HM
Acta Haematol; 2001; 106(4):190-207. PubMed ID: 11815717
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-6: an angiogenic target in solid tumours.
Middleton K; Jones J; Lwin Z; Coward JI
Crit Rev Oncol Hematol; 2014 Jan; 89(1):129-39. PubMed ID: 24029605
[TBL] [Abstract][Full Text] [Related]
43. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
Vacca A; Ria R; Ribatti D; Semeraro F; Djonov V; Di Raimondo F; Dammacco F
Haematologica; 2003 Feb; 88(2):176-85. PubMed ID: 12604407
[TBL] [Abstract][Full Text] [Related]
44. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC; Leenders WP
Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
[TBL] [Abstract][Full Text] [Related]
45. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic options to target angiogenesis in human malignancies.
Herbst RS
Expert Opin Emerg Drugs; 2006 Nov; 11(4):635-50. PubMed ID: 17064223
[TBL] [Abstract][Full Text] [Related]
47. Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP.
Pratheeshkumar P; Kuttan G
Eur J Pharmacol; 2011 Apr; 656(1-3):10-8. PubMed ID: 21256125
[TBL] [Abstract][Full Text] [Related]
48. Angiogenesis inhibitors in the treatment of lung cancer.
Sun S; Schiller JH
Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
[TBL] [Abstract][Full Text] [Related]
49. Antiangiogenic therapies in non-Hodgkin's lymphoma.
Ruan J
Curr Cancer Drug Targets; 2011 Nov; 11(9):1030-43. PubMed ID: 21933106
[TBL] [Abstract][Full Text] [Related]
50. Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer.
Korpanty G; Smyth E
Curr Pharm Des; 2012; 18(19):2680-701. PubMed ID: 22390756
[TBL] [Abstract][Full Text] [Related]
51. Angiogenic switch in multiple myeloma.
Giuliani N; Colla S; Rizzoli V
Hematology; 2004; 9(5-6):377-81. PubMed ID: 15763977
[TBL] [Abstract][Full Text] [Related]
52. Angiogenesis in acute and chronic leukemias.
Dickson DJ; Shami PJ
Leuk Lymphoma; 2001; 42(5):847-53. PubMed ID: 11697639
[TBL] [Abstract][Full Text] [Related]
53. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies.
Rajkumar SV; Mesa RA; Tefferi A
J Hematother Stem Cell Res; 2002 Feb; 11(1):33-47. PubMed ID: 11847002
[TBL] [Abstract][Full Text] [Related]
54. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
Adjei AA
Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S74-8. PubMed ID: 17382028
[TBL] [Abstract][Full Text] [Related]
55. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
[TBL] [Abstract][Full Text] [Related]
56. Biological aspects of angiogenesis in multiple myeloma.
Otjacques E; Binsfeld M; Noel A; Beguin Y; Cataldo D; Caers J
Int J Hematol; 2011 Dec; 94(6):505-18. PubMed ID: 22086206
[TBL] [Abstract][Full Text] [Related]
57. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
[TBL] [Abstract][Full Text] [Related]
58. Angiogenesis in hematologic malignancies and its clinical implications.
Yang R; Han ZC
Int J Hematol; 2002 Apr; 75(3):246-56. PubMed ID: 11999351
[TBL] [Abstract][Full Text] [Related]
59. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.
Eleutherakis-Papaiakovou V; Karali M; Kokkonouzis I; Tiliakos I; Dimopoulos MA
Leuk Lymphoma; 2003 Jun; 44(6):937-48. PubMed ID: 12854891
[TBL] [Abstract][Full Text] [Related]
60. Angiogenesis and angiogenic mediators in haematological malignancies.
Mangi MH; Newland AC
Br J Haematol; 2000 Oct; 111(1):43-51. PubMed ID: 11091181
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
